Herpes viral infection is currently the most common of viral diseases. Diseases caused by herpes simplex virus are second only to cardiovascular diseases and cancers. Phytotherapy is of particular interest as it combines a wide range of pharmacological effects and the absence of adverse reactions. Phytodrugs containing various biologically active substances gently influence the body, restore the disrupted functions of the immune system and can be recommended for use in patients of all age groups. Objective. To examine the antiviral and antirelapse efficacy of Panavir phytodrug in dentistry. Material and methods. A total of 36 patients with symptoms of chronic recurrent herpetic stomatitis and cheilitis were examined and treated. The antiviral efficacy of Panavir was assessed by the rate of elimination of inflammation symptoms, a decrease in manifestations of herpes infection and emergence of new lesions during the drug therapy. The dynamic follow-up was 12 months after the treatment. Results. A decrease in local manifestations was recorded in most patients on day 3-4 of the treatment. Clinical manifestations of inflammatory and infectious symptoms of herpes disappeared in all patients after 10-15 days of follow-up. To evaluate the immune response, the incidence of herpes infection exacerbation was analyzed: within 6 months after treatment the relapse was observed in 48% of patients; after 12 months, in 65%. Conclusion. The administration of Panavir was associated with positive antiviral and antirelapse effects.